Prestige BioPharma Past Earnings Performance
Past criteria checks 0/6
Prestige BioPharma's earnings have been declining at an average annual rate of -7.2%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 135.8% per year.
Key information
-7.2%
Earnings growth rate
-5.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 135.8% |
| Return on equity | -10.7% |
| Net Margin | -4,777.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Prestige BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 689 | -32,921 | 45,442 | 0 |
| 31 Mar 24 | 988 | -32,443 | -7,198 | 0 |
| 31 Dec 23 | 349 | -45,358 | -4,853 | 0 |
| 30 Sep 23 | 229 | -51,336 | 64,497 | 0 |
| 30 Jun 23 | 162 | 17,569 | -12,376 | 0 |
| 31 Mar 23 | 0 | -74,934 | 140,014 | 0 |
| 31 Dec 22 | 0 | -146,311 | 133,256 | 0 |
| 30 Sep 22 | 0 | -141,415 | 53,627 | 0 |
| 30 Jun 22 | 0 | -211,450 | 118,594 | 0 |
| 31 Mar 22 | 0 | -107,494 | 29,287 | 0 |
| 31 Dec 21 | 0 | -31,968 | 25,471 | 0 |
| 30 Sep 21 | 0 | -17,288 | 19,382 | 0 |
| 30 Jun 21 | 0 | -7,391 | 16,432 | 0 |
| 31 Mar 21 | 0 | -17,069 | 21,454 | -2,646 |
Quality Earnings: A950210 is currently unprofitable.
Growing Profit Margin: A950210 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A950210 is unprofitable, and losses have increased over the past 5 years at a rate of 7.2% per year.
Accelerating Growth: Unable to compare A950210's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A950210 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A950210 has a negative Return on Equity (-10.69%), as it is currently unprofitable.